Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Jul 5;26(Suppl 1):7–10. doi: 10.1002/clc.4960261304

New dimension of statin action on apoB atherogenicity

M John Chapman 1,✉, Muriel Caslake 2, Chris Packard 2, Fergus McTaggart 3
PMCID: PMC6653840  PMID: 12539816

Abstract

Newer, more effective statins are powerful agents for reducing elevated levels of low‐density lipoprotein (LDL) cholesterol and thereby lowering the risk of coronary heart disease (CHD) and related adverse events. Although LDL remains the primary target of therapy for reducing CHD risk, increased interest is focusing on apolipoprotein B (apoB)‐containing lipoprotein subfractions—particularly very‐low‐density lipoprotein (VLDL), VLDL remnants, and intermediate‐density lipoproteins (IDL)—as secondary targets of therapy. Elevated apoB is known to be an important risk factor for CHD, and dysregulation of the metabolism of apoB‐containing lipoproteins is involved in the progression of atherosclerosis. Statins reduce circulating concentrations of atherogenic apoB‐containing lipoproteins by decreasing the production of VLDL in the liver and, thus, the production of VLDL remnants and LDL. Statins also increase the clearance of these particles through upregulation of LDL receptors in the liver. Efforts to develop statins with enhanced lipid‐modifying properties are ongoing. The optimal statin would offer a high degree of inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, a prolonged duration of action, hepatic selectivity for maximal upregulation of LDL receptors, and a low potential for drug–drug interactions. Recent studies have shown that rosuvastatin, a new agent in this class, demonstrates these qualities. Rosuvastatin is a highly effective inhibitor of HMG‐CoA reductase, is relatively nonlipophilic, has a half‐life of approximately 20 h, exhibits hepatic selectivity, has little systemic availability, and has a low potential for drug–drug interactions because of its limited degree of metabolism by the cytochrome P‐450 system. A recent double‐blind, crossover study revealed that treatment with rosuvastatin resulted in marked reductions in apoB‐containing lipoproteins in patients with type IIa or IIb dyslipidemia. By reducing the number of atherogenic lipoprotein particles, rosuvastatin decreases the atherosclerotic burden in hyperlipidemic patients at high risk for CHD and related adverse outcomes.

Keywords: apolipoprotein B, atherosclerosis, dyslipidemia, rosuvastatin, statins

Full Text

The Full Text of this article is available as a PDF (77.1 KB).

References

  • 1. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Inter N Med 1988; 148: 36–69 [PubMed] [Google Scholar]
  • 2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015–3023 [PubMed] [Google Scholar]
  • 3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 235: 2486–2497 [DOI] [PubMed] [Google Scholar]
  • 4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
  • 5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
  • 6. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
  • 7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
  • 8. Lamarche B, Moorjani S, Lupien PJ, Cantrin B, Bernard P‐M, Dagenais GR, Després J‐P: Apolipoprotein A‐I and B levels and the risk of ischemic heart disease during a five‐year follow‐up of men in the Québec Cardiovascular Study. Circulation 1996; 94: 273–278 [DOI] [PubMed] [Google Scholar]
  • 9. Tomkin GH, Owens D: Abnormalities in apo B‐containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001; 17: 27–43 [DOI] [PubMed] [Google Scholar]
  • 10. Hahn SE, Goldberg DM: Factors affecting the regulation of apo B secretion by liver cells. J Clin Lab Anal 1995; 9: 431–449 [DOI] [PubMed] [Google Scholar]
  • 11. Goldberg DI, Beltz WF, Pittman RC: Evaluation of pathways for the cellular uptake of high‐density lipoprotein cholesterol esters in rabbits. J Clin Invest 1991; 87: 331–346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Brown MS, Goldstein JL: A receptor‐mediated pathway for cholesterol homeostasis. Science 1986; 232: 34–47 [DOI] [PubMed] [Google Scholar]
  • 13. Vega GL, Grundy SM: Effect of statins on metabolism of apo‐B‐containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998; 81 (suppl 4A): 36B–42B [DOI] [PubMed] [Google Scholar]
  • 14. Forster RF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ: Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002; 164: 129–145 [DOI] [PubMed] [Google Scholar]
  • 15. Milosavljevic D, Griglio S, Le Naour G, Chapman J: Preferential reduction of VLDL‐1 particle number by fenofibrate in type IIB hyperlipidemia: Consequences for uptake by human monocyte‐derived macrophages. Atherosclerosis 2001; 155: 251–260 [DOI] [PubMed] [Google Scholar]
  • 16. Chapman JM: Atherogenicity of low‐density lipoproteins: mechanisms In Plasma Lipids and Their Role in Disease (Eds. Barter PJ, Rye KA.), p. 69–84. Amsterdam, The Netherlands: Harwood Academic Publishers, 1999. [Google Scholar]
  • 17. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of rosuvastatin, a new 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87 (suppl): 28B–32B [DOI] [PubMed] [Google Scholar]
  • 18. Shephard J: The statin era: In search of the ideal lipid regulating agent. Heart 2001; 85: 259–264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Buckett L, Ballard P, Davidson R, Dunkley C, Martin L, Stafford J, McTaggart F: Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non‐hepatic cells (abstract MoP29:W6). Atherosclerosis 2000; 151: 41 [Google Scholar]
  • 20. Smith G, Davidson R, Bloor S, Burns K, Calman C, McAulay P, Torr N, Ward W, McTaggart F: Pharmacological properties of ZD4522: A new HMG‐CoA reductase inhibitor (abstract MoP20:W6). Atherosclerosis 2000; 151: 39 [Google Scholar]
  • 21. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG‐CoA reductase. Science 2001; 292: 1160–1164 [DOI] [PubMed] [Google Scholar]
  • 22. McCormick AD, McKillop D, Bulters CJ, Miles GS, Baba T, Touchi A, Yamaguchi Y: ZD4522: An HMG‐CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems (abstract 46). J Clin Pharmacol 2000; 40: 1055 [Google Scholar]
  • 23. Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low‐density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504–508 [DOI] [PubMed] [Google Scholar]
  • 24. Blumenthal RS: Statins: Effective antiatherosclerotic therapy. Am Heart J 2000; 139: 577–583 [DOI] [PubMed] [Google Scholar]
  • 25. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498–511 [DOI] [PubMed] [Google Scholar]
  • 26. Maron DJ, Fazio S, Linton MP: Current perspectives on statins. Circulation 2000; 101: 207–213 [DOI] [PubMed] [Google Scholar]
  • 27. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG‐CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678–682 [DOI] [PubMed] [Google Scholar]
  • 28. Caslake MJ, Stewart G, Day S, Daly E, Nwose OM, Chapman MJ, Durrington P, Laggner P, Pears J, Packard CJ: Rosuvastatin normalises atherogenic levels of apo B‐containing lipoprotein subfractions. Int J Clin Pract 2002; 124 (suppl): 8 [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES